Global expansion StageBio operates eight US sites and one in Germany, serving Americas, Europe, Australia, and Asia. Potential sales opportunity: upsell services across regions, leverage cross-border GLP-compliant histology and pathology capabilities for multi-site trials and global studies.

Integrated offerings Comprehensive services including tissue analysis, efficacy, toxicology, pathology reporting, immunohistochemistry, and neuropathology. Potential sales opportunity: position StageBio as a one-stop partner for preclinical to clinical path operations, offering bundled solutions to trial sponsors.

Strategic leadership Recent leadership appointments and awards indicate growing credibility and market visibility. Potential sales opportunity: engage with Head of Commercial and CEO to accelerate enterprise contracts and long-term partnerships, leveraging recognized industry leadership.

Partnerships & tech Strategic partnership with Pathcore and investment in facility and technology infrastructure. Potential sales opportunity: propose joint digital pathology and data analytics solutions, and expand offerings with advanced image analysis and archiving capabilities to tech-forward biopharma customers.

Targeted markets Active participation in major industry events (ARVO, SOT) and GLP-compliant scope across biopharma, medical devices, and CROs. Potential sales opportunity: pursue event-driven lead generation, sponsor sessions, and tailor messaging to researchers needing histology, opacity in regulatory studies, and neuropathology expertise.